Pictet Asset Management
CYTK icon

Pictet Asset Management’s Cytokinetics CYTK Stock Holding History

Pictet Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.3M Sell
750,953
-6,610
-0.9% -$420K 0.05% 314
2025
Q4 		$48M Sell
757,563
-387,995
-34% -$24.1M 0.05% 332
2025
Q3 		$62.9M Sell
1,145,558
-400,833
-26% -$16.5M 0.06% 278
2025
Q2 		$51.1M Sell
1,546,391
-409,936
-21% -$14.3M 0.05% 312
2025
Q1 		$78.9M Buy
1,956,327
+44,328
+2% +$2.04M 0.09% 236
2024
Q4 		$89.9M Sell
1,911,999
-176,568
-8% -$9.17M 0.1% 215
2024
Q3 		$110M Buy
2,088,567
+320,405
+18% +$17.9M 0.12% 186
2024
Q2 		$95.8M Buy
1,768,162
+14,516
+0.8% +$876K 0.11% 195
2024
Q1 		$123M Buy
1,753,646
+381,402
+28% +$29.5M 0.13% 184
2023
Q4 		$115M Sell
1,372,244
-875,199
-39% -$31.7M 0.13% 186
2023
Q3 		$66.2M Buy
+2,247,443
New +$74.8M 0.08% 244

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pictet Asset Management's CYTK Position: Q1 2026 in Review

Pictet Asset Management reduced its Cytokinetics (CYTK) stake by 0.87% in Q1 2026, selling an estimated $420K and leaving 750,953 shares worth $49.3M. The position accounts for 0.05% of the portfolio, ranked #314.

Pictet Asset Management first reported a position in CYTK in Q3 2023 and has held it in 11 quarters since. The position peaked at $123M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Pictet Asset Management held 750,953 shares of Cytokinetics worth $49.3M as of Q1 2026.
  • Pictet Asset Management sold 6,610 Cytokinetics shares in Q1 2026, an estimated $420K.
  • Cytokinetics made up 0.05% of Pictet Asset Management's portfolio in Q1 2026, its #314 holding.
  • Pictet Asset Management first reported a position in Cytokinetics in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Cytokinetics position peaked at $123M in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.